Drug Evaluation

What role will ensifentrine play in the future treatment of chronic obstructive pulmonary disease patients? Implications from recent clinical trials

*Author for correspondence:

E-mail Address: mario.cazzola@uniroma2.it

https://orcid.org/0000-0003-4895-9707

Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome ‘Tor Vergata’, 00133, Rome, Italy

Search for more papers by this author

Clive Page

https://orcid.org/0000-0002-9358-3799

Pulmonary Pharmacology Unit, Institute of Pharmaceutical Science, King's College London, SE1 9NH, London, UK

Search for more papers by this author

Luigino Calzetta

Unit of Respiratory Diseases & Lung Function, Department of Medicine & Surgery, University of Parma, 43126, Parma, Italy

Search for more papers by this author

Dave Singh

Medicines Evaluation Unit, University of Manchester & Manchester University NHS Foundation Trust, M23 9QZ, Manchester, UK

Search for more papers by this author

Paola Rogliani

Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome ‘Tor Vergata’, 00133, Rome, Italy

Search for more papers by this author

Maria Gabriella Matera

Unit of Pharmacology, Department of Experimental Medicine, University of Campania ‘Luigi Vanvitelli’, 80138, Naples, Italy

Search for more papers by this author

Published Online:2 Oct 2023https://doi.org/10.2217/imt-2023-0136

View article

Abstract

Data from the phase III ENHANCE clinical trials provide compelling evidence that ensifentrine, an inhaled ‘bifunctional’ dual phosphodiesterase 3/4 inhibitor, can provide additional benefit to existing treatments in patients with chronic obstructive pulmonary disease and represents a ‘first-in-class’ drug having bifunctional bronchodilator and anti-inflammatory activity in a single molecule. Ensifentrine, generally well tolerated, can provide additional bronchodilation when added to muscarinic receptor antagonists or β₂-agonists and reduce the exacerbation risk. This information allows us to consider better the possible inclusion of ensifentrine in the future treatment of chronic obstructive pulmonary disease. However, there is less information on whether it provides additional benefit when added to inhaled corticosteroid or ‘triple therapy’ and, therefore, when this drug is best utilized in clinical practice.

Plain language summary

Chronic obstructive pulmonary disease (COPD) is the name for a group of lung conditions that cause breathing difficulties/airflow limitations. The airflow limitation is not completely reversible and is associated with a state of chronic inflammation of lung tissue. Treatment of the disease is still heavily dependent on the use of medications called bronchodilators and corticosteroids. However, corticosteroids have little-to-no impact on the underlying inflammation in most COPD patients. Therefore, innovative anti-inflammatory approaches are required. In this context, single molecules that are capable of simultaneously inducing bronchodilation, relaxing the muscles in the lungs and widening the airways (bronchi), and anti-inflammatory activity are a highly intriguing possibility for treating COPD. One approach is to develop drugs that can simultaneously inhibit enzymes called phosphodiesterase (PDE)3 and PDE4. Enzymes are proteins that help speed up metabolism, or the chemical reactions in our bodies. PDE4 inhibitors are intracellular enzymes (work inside the cell) expressed in most inflammatory cells, even in neutrophils (a type of white blood cells), which are involved in the pathogenesis of COPD, where an infection turns into a disease. However, its inhibition does not produce severe bronchodilator effects, which is instead obtained by inhibiting PDE3, the PDE isoenzyme (a different form of the same enzyme) that is predominantly expressed in airway smooth muscle cells. A treatment called ensifentrine is a dual PDE3/4 inhibitor (inhibits both PDE3 and PDE4). Two recent phase III studies (ENHANCE-1 and ENHANCE-2) have shown that it induces significant bronchodilation and reduces the risk of COPD worsening, exerting an anti-inflammatory effect. Data from the ENHANCE studies also showed the benefit of adding ensifentrine to treatment with bronchodilators. Certainly, the drug represents a useful therapeutic option, but further clinical studies are needed to be able to correctly position ensifentrine in the context of regular COPD treatment.

Tweetable abstract

Ensifentrine, an inhaled ‘bifunctional’ dual PDE3/4 inhibitor, can provide additional benefit to existing treatments in patients with COPD and represents a ‘first in class’ drug having bifunctional bronchodilator and anti-inflammatory activity in a single molecule.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Boswell-Smith V, Spina D, Oxford AW, Comer MB, Seeds EA, Page CP. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]. J. Pharmacol. Exp. Ther. 318(2), 840–848 (2006).
Medline CASGoogle Scholar
2. Cazzola M, Page C. An inhaled “bifunctional” dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD. Eur. Respir. J. 52(5), 1801675 (2018).
MedlineGoogle Scholar
3. Page CP. Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. Int. Arch. Allergy Immunol. 165(3), 152–164 (2014).
Medline CASGoogle Scholar
4. Schmidt DT, Watson N, Dent G et al. The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitised human airways. Br. J. Pharmacol. 131(8), 1607–1618 (2000).
Medline CASGoogle Scholar
5. Abbott-Banner KH, Page CP. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases. Basic Clin. Pharmacol. Toxicol. 114, 365–376 (2014). • Dual phosphodiesterase (PDE3)/4 and PDE4 inhibitors: novel treatments for chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases.
Medline CASGoogle Scholar
6. Beute J, Lukkes M, Koekoek EP et al. A pathophysiological role of PDE3 in allergic airway inflammation. JCI Insight. 3(2), e94888 (2018).
MedlineGoogle Scholar
7. Cobb BR, Fan L, Kovacs TE, Sorscher EJ, Clancy JP. Adenosine receptors and phosphodiesterase inhibitors stimulate Cl^- secretion in Calu-3 cells. Am. J. Respir. Cell Mol. Biol. 29(3 Pt 1), 410–418 (2003).
Medline CASGoogle Scholar
8. Barnes AP, Livera G, Huang P et al. Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. J. Biol. Chem. 280(9), 7997–8003 (2005).
Medline CASGoogle Scholar
9. Page C, Cazzola M. Bifunctional drugs for the treatment of respiratory diseases. Handb. Exp. Pharmacol. 237, 197–212 (2017).
Medline CASGoogle Scholar
10. Cazzola M, Page C, Calzetta L, Matera MG. Ensifentrine (RPL554): an inhaled ‘bifunctional’ dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. Pharm. Pat. Anal. 7(6), 249–257 (2018).
Medline CASGoogle Scholar
11. Cazzola M, Calzetta L, Rogliani P, Matera MG. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opin. Investig. Drugs. 28(10), 827–833 (2019).
Medline CASGoogle Scholar
12. Donohue JF, Rheault T, MacDonald-Berko M, Bengtsson T, Rickard K. Ensifentrine as a novel, inhaled treatment for patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 18, 1611–1622 (2023). • Nonclinical data, as well as phase I and II safety and efficacy outcomes of nebulized ensifentrine relevant to the maintenance therapy of COPD patients, are summarized in this article.
Medline CASGoogle Scholar
13. Calzetta L, Page CP, Spina D et al. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J. Pharmacol. Exp. Ther. 346(3), 414–423 (2013).
Medline CASGoogle Scholar
14. Calzetta L, Cazzola M, Page CP, Rogliani P, Facciolo F, Matera MG. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm. Pharmacol. Ther. 32, 15–23 (2015).
Medline CASGoogle Scholar
15. Venkatasamy R, Spina D. Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility. Br. J. Pharmacol. 173(15), 2335–2351 (2016).
Medline CASGoogle Scholar
16. Franciosi LG, Diamant Z, Banner KH et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir. Med. 1(9), 714–727 (2013).
Medline CASGoogle Scholar
17. Turner MJ, Matthes E, Billet A et al. The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia. Am. J. Physiol. Lung Cell. Mol. Physiol. 310(1), L59–L70 (2016).
MedlineGoogle Scholar
18. Cazzola M, Page C, Matera MG. Ensifentrine: A first-in-class bifunctional drug for the treatment of chronic obstructive pulmonary disease. etouchREVIEWS Respir. Pulmon. Dis. 7(2), 48–53 (2022). • Highlights the unanswered questions that emerged from analyzing phase I and II clinical development data concerning the possible positioning of ensifentrine in the COPD treatment scheme.
Google Scholar
19. Rickard K, Rheault T, Bengtsson T. Twice-daily, nebulized ensifentrine produced significant improvement in week 12 lung function: subgroup analysis in the phase 3 trial ENHANCE-2. Am. J. Respir. Crit. Care Med. 207, A2838 (2023).
Google Scholar
20. Barjaktarevic IZ, Rheault T, Bengtsson T, Rickard K. Ensifentrine reduced healthcare resource utilization in subjects with COPD: results from ENHANCE-2, a phase 3 trial of ensifentrine, a dual PDE3/4 inhibitor. Am. J. Respir. Crit. Care Med. 207, A2839 (2023).
Google Scholar
21. Anzueto A, Rheault T, Bengtsson T, Rickard K. Treatment with ensifentrine, a dual PDE3 and PDE4 inhibitor, significantly reduced exacerbation rate and risk in subjects with COPD: sub-group results from the phase 3 trial, ENHANCE-2. Am. J. Respir. Crit. Care Med. 207, A4998 (2023).
Google Scholar
22. Ferguson GT, Rheault T, Bengtsson T, Rickard K. Ensifentrine, a dual inhibitor of PDE3 and PDE4, reduces the risk of exacerbation regardless of background medication use: a sub-group analysis of ENHANCE-2, a phase 3 trial. Am. J. Respir. Crit. Care Med. 207, A4999 (2023).
Google Scholar
23. Rheault T, Bengtsson T, Rickard K. Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, in moderate and severe COPD: symptoms, quality of life and health status from the phase 3 trial ENHANCE-2. Am. J. Respir. Crit. Care Med. 207, A5000 (2023).
Google Scholar
24. Siler TM, Rickard K, Bengtsson T, Rheault T. Safety results from dual PDE3/4 inhibitor ensifentrine: gastrointestinal and cardiovascular safety from a 24-week phase 3 trial, ENHANCE-2. Am. J. Respir. Crit. Care Med. 207, A5003 (2023).
Google Scholar
25. Siler TM, Rheault T, Bengtsson T, Rickard K. Twice-daily, nebulized ensifentrine significantly improves lung function: sub-group analysis in the phase 3 trial, ENHANCE-1. Am. J. Respir. Crit. Care Med. 207, A5004 (2023).
Google Scholar
26. Sciurba F, Wise R, Rheault T, Bengtsson T, Rickard K. Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, improves lung function, symptoms, quality of life and reduces exacerbation rate and risk in the ENHANCE-1 phase 3 trial of ensifentrine in COPD. Am. J. Respir. Crit. Care Med. 207, A5006 (2023).
Google Scholar
27. Sciurba F, Rheault T, Bengtsson T, Rickard K. Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, significantly improves COPD symptoms and quality of life in the phase 3 ENHANCE-1 trial. Am. J. Respir. Crit. Care Med. 207, A5007 (2023).
Google Scholar
28. Barjaktarevic IZ, Rheault T, Bengtsson T, Rickard K. Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, significantly reduces annualized exacerbations and delays the time to first exacerbation in COPD: pooled sub-group analyses of ENHANCE-1 and ENHANCE-2 phase 3 trials. Am. J. Respir. Crit. Care Med. 207, A5008 (2023).
Google Scholar
29. Sciurba F, Anzueto A, Rheault T, Bengtsson T, Rickard K. Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, improves lung function, symptoms, quality of life and reduces exacerbation rate and risk in patients with COPD: results from replicate phase 3 trials. Am. J. Respir. Crit. Care Med. 207, A5005 (2023).
Google Scholar
30. Anzueto A, Barjaktarevic IZ, Siler TM et al. Ensifentrine, a novel PDE3 and PDE4 inhibitor for the treatment of COPD: randomized, double-blind, placebo-controlled, multicenter, phase III trials (the ENHANCE trials). Am. J. Respir. Crit. Care Med. 208(4), 406–416 (2023). •• Key article that, by reporting the results of the two ENHANCE program studies, helps to understand the real position of ensifentrine in treating COPD.
Medline CASGoogle Scholar
31. Jensen B. Verona Pharma: Targeting the large COPD market (2023). https://seekingalpha.com/article/4625531-verona-pharma-targeting-the-large-copd-market?mailingid=32348864&messageid=must_reads&serial=32348864.3878154&utm_campaign=Must%2BReads%2Brecurring%2B2023-08-09&utm_content=seeking_alpha&utm_medium=email&utm_source=seeking_alpha&utm_term=must_reads
Google Scholar
32. Singh D, Abbott-Banner K, Bengtsson T, Newman K. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. Eur. Respir. J. 52(5), 1801074 (2018).
MedlineGoogle Scholar
33. Singh D, Martinez FJ, Watz H, Bengtsson T, Maurer BT. A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. Respir. Res. 21(1), 47 (2020). •• Important 4-week phase IIb study that showed that ensifentrine monotherapy was effective and safe and supported the continuing development of this PDE3/4 inhibitor in COPD.
Medline CASGoogle Scholar
34. Rickard K, Rheault T, Bengtsson T. Additional bronchodilation by ensifentrine, a dual PDE3/4 inhibitor, when combined with a LAMA/LABA in patients with moderate to severe COPD. Am. J. Respir. Crit. Care Med. 201, A4298 (2020).
Google Scholar
35. Agustí A, Celli BR, Criner GJ et al. Global Initiative for Chronic Obstructive Lung Disease 2023 report: GOLD executive summary. Eur. Respir. J. 61(4), 2300239 (2023).
MedlineGoogle Scholar
36. Cazzola M, Hanania NA, Page CP, Matera MG. Novel anti-inflammatory approaches to COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 18, 1333–1352 (2023).
Medline CASGoogle Scholar
37. Cazzola M, Ora J, Calzetta L, Rogliani P, Matera MG. Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today? Expert Opin. Pharmacother. 23(8), 917–927 (2022).
MedlineGoogle Scholar
38. Calzetta L, Coppola A, Ritondo BL, Matino M, Chetta A, Rogliani P. The impact of muscarinic receptor antagonists on airway inflammation: a systematic review. Int. J. Chron. Obstruct. Pulmon. Dis. 16, 257–279 (2021).
MedlineGoogle Scholar
39. Beeh KM, Burgel PR, Franssen FME et al. How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am. J. Respir. Crit. Care Med. 196(2), 139–149 (2017).
Medline CASGoogle Scholar
40. Rab A, Rowe SM, Raju SV, Bebok Z, Matalon S, Collawn JF. Cigarette smoke and CFTR: implications in the pathogenesis of COPD. Am. J. Physiol. Lung Cell. Mol. Physiol. 305(8), L530–L541 (2013).
Medline CASGoogle Scholar
41. Mall MA, Hartl D. CFTR: cystic fibrosis and beyond. Eur. Respir. J. 44(4), 1042–1054 (2014).
Medline CASGoogle Scholar
42. Turner MJ, Matthes E, Billet A et al. The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia. Am. J. Physiol. Lung Cell. Mol. Physiol. 310(1), L59–L70 (2016).
MedlineGoogle Scholar
43. Bjermer L, Abbott-Banner K, Newman K. Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma. Pulm. Pharmacol. Ther. 58, 101814 (2019).
Medline CASGoogle Scholar
44. Turner MJ, Abbott-Banner K, Thomas DY, Hanrahan JW. Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis. Pharmacol. Ther. 224, 107826 (2021).
Medline CASGoogle Scholar

Vol. 15, No. 18

Metrics

Downloaded 194 times

History

Received 26 June 2023

Accepted 18 September 2023

Published online 2 October 2023

Published in print December 2023

Information

Keywords

Financial disclosure

M Cazzola reports receiving grants and personal fees from Verona Pharma. M Cazzola and L Calzetta have patents 9717732, 9700558, 20160008363, 20160000790 and 20170266190 licensed to Verona Pharma. C Page reports receiving grants and personal fees from, and holds equity in, Verona Pharma. D Singh reports personal fees from Verona Pharma. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

PDF download